The world's first nanoantibody, Caplacizumab, has again been approved by NICE to treat clotting disorders in patients with rare diseases, following the FDA and EMA

The Uk's National Institute for Health and Clinical Excellence (NICE) has approved Sanofi's Caplacizumab for the treatment of acquired thrombosis plateboard reduced cyanosis (aTTP), a rare and potentially life-threatening blood clotting disorder.
approval of this NICE applies to the treatment of acute seizures in patients over 12 years of age who weigh at least 40 kg.
Caplacizumab is a nanoantibody (VHH) that targets vascular haemophilia factors (vWF), which reduce plateplate adhesion and consumption by blocking the interaction of vWF aggregates with plateplates.
: Approved data based on the HERCULES III study, which compared the efficacy and safety of caplacizumab in 145 patients with atTP.
results showed that caplacizumab reduced the time it takes for plate plate plates to return to normal levels compared to placebos, and reduced the risk of death, TTP recurrence, and thrombosis in blood vessels.
the recurrence of TTP after treatment with Caplacizumab (Photo: Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 Jan 24;380 (4):335-346.)